Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INTIGT

Financiado

Identification of novel targets to improve glioblastoma therapy

Glioblastoma (GBM) is the most common malignant primary brain tumour in adults. The current standard of care is surgical resection of GBM tumours followed by chemotherapy and ionizing radiation (IR). Despite these intense efforts,... ver más

31/08/2025

UBx

212K€

Presupuesto del proyecto: 212K€

Líder del proyecto

UNIVERSITE DE BORDEAUX No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-24

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100%

1 Participantes

UBx

211.75K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GLIOBID Guiding glioblastoma treatments by decrypting tumor biomecha... 284K€ Cerrado

SAF2015-65175-R RESISTENCIA MEDIADA POR EL MICROAMBIENTE EN GLIOBLASTOMA: CA... 145K€ Cerrado

RESISTANCEPROGRAMS Tumor recurrence and therapeutic resistance: exploring and e... 2M€ Cerrado

PDC2022-133826-I00 PLATAFORMA DE CO-CULTIVO IN VITRO CON GLIO-ORGANOIDES PARA B... 115K€ Cerrado

STIC-GBM Spatio-temporal dynamics of immune circuitry in glioblastoma... 174K€ Cerrado

INTIGT Identification of novel targets to improve glioblastoma ther... 212K€ Cerrado

Duración del proyecto: 33 meses Fecha Inicio: 2022-11-24
Fecha Fin: 2025-08-31

Líder del proyecto

UNIVERSITE DE BORDEAUX No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 212K€

Descripción del proyecto Glioblastoma (GBM) is the most common malignant primary brain tumour in adults. The current standard of care is surgical resection of GBM tumours followed by chemotherapy and ionizing radiation (IR). Despite these intense efforts, GBM tumours remain incurable and the median survival rate of GBM patients remains only ~15 months. This dismal clinical outcome underscores the urgent need for novel therapeutic strategies for GBM. At the cellular level, GBM tumours contain a rare population of self-renewing, highly invasive stem cells termed brain tumour stem cells (BTSCs) that are endowed with properties to proliferate, spur the growth of new tumours, and at the same time, evade IR and chemotherapy. Thus eradicating BTSCs in tumour bulk represents a promising approach to fight brain cancer at its root. However, there are presently no treatments targeting BTSCs in GBM. Recent preliminary data obtained by the applicant at McGill University (Montreal, Canada) led to the hypothesis that a novel signalling pathway, galectin1/HOXA5, controls BTSC behaviour and represents a promising target to eradicate BTSCs. Thus, the applicant will join the Laboratoire de l’Angiogenèse et du Microenvironnement des Cancers at University of Bordeaux to test this hypothesis, under the supervision of Pr. Bikfalvi. The host, the supervisor and the candidate represents the perfect match to realise this proposal and the project is designed to bring forth a two-transfer of knowledge between the host and the candidate. The advanced techniques and transferable skills that the candidate acquires through this research will largely broaden his competencies and increase his employability as an independent researcher in the field of neuro-oncology. Results generated through this proposal will be innovative and of clinical relevance for GBM patients. This study has the potential to open new therapeutic avenues and pave the way for future clinical trials for better treatment of these deadly tumours.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores